Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INCACAD · Entity 3913 | Director | May 29, 2026 | June 01, 2026 |
| ARATANA THERAPEUTICS, INC.PETX · Entity 155913 | Director | July 27, 2018 | July 30, 2018 |
| DYNAVAX TECHNOLOGIES CORPDVAX · Entity 66930 | Director | May 30, 2019 | May 31, 2019 |
| Edgewise Therapeutics, Inc.EWTX · Entity 3965 | Director | June 05, 2026 | June 17, 2026 |
| Mirum Pharmaceuticals, Inc.MIRM · Entity 2416 | Director | June 15, 2026 | June 18, 2026 |
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Director | June 10, 2026 | June 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACADIA PHARMACEUTICALS INC
Report date May 29, 2026 · Filed June 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,202 |
Reported balance
After 2026-05-29 transaction · row 1
1 source rowRow 1 · 2026-05-29 · Exercise / conversion · Acquired 8,107 · Balance 23,202 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-29 · Exercise / conversion · Disposed 8,107 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2: The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 9,311 |
Reported balance
After 2026-05-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-29 · Grant · Acquired 9,311 · Balance 9,311 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended. |
| Director Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.66 · Expires 2036-05-28 | Direct | 16,004 |
Reported balance
After 2026-05-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-29 · Grant · Acquired 16,004 · Balance 16,004 F3: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
F2: The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held.
F3: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders.
F4: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended.
ARATANA THERAPEUTICS, INC.
Report date July 27, 2018 · Filed July 30, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,500 |
Reported balance
After 2018-07-27 transaction · row 1
1 source rowRow 1 · 2018-07-27 · Grant · Acquired 4,500 · Balance 13,500 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.36 · Expires 2028-07-26 | Direct | 7,500 |
Reported balance
After 2018-07-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-07-27 · Grant · Acquired 7,500 · Balance 7,500 F1: Vests on the earlier of (i) the first anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's next annual meeting of stockholders following the date of grant, subject to continued service as a member of the Board of Directors of the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Vests on the earlier of (i) the first anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's next annual meeting of stockholders following the date of grant, subject to continued service as a member of the Board of Directors of the Issuer through such vesting date.
DYNAVAX TECHNOLOGIES CORP
Report date May 30, 2019 · Filed May 31, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.97 · Expires 2026-05-29 | Direct | 15,000 |
Reported balance
After 2019-05-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-05-30 · Grant · Acquired 15,000 · Balance 15,000 F2: Not applicable. F1: This option vests fully on May 30, 2020, on the one year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests fully on May 30, 2020, on the one year anniversary of the grant date.
F2: Not applicable.
Edgewise Therapeutics, Inc.
Report date June 05, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.59 · Expires 2036-06-05 | Direct | 16,377 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 16,377 · Balance 16,377 F1: 100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder.
Mirum Pharmaceuticals, Inc.
Report date June 15, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $101.00 · Expires 2036-06-14 | Direct | 3,772 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 3,772 · Balance 3,772 F1: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. |
| Deferred Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,980 |
Reported balance
After 2026-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-15 · Grant · Acquired 1,980 · Balance 1,980 F2: Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.
F2: Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer.
Pacira BioSciences, Inc.
Report date June 10, 2026 · Filed June 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,120 |
Reported balance
After 2026-06-10 transaction · row 1
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 6,405 · Balance 30,120 F1: Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.42 · Expires 2036-06-10 | Direct | 10,891 |
Reported balance
After 2026-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-10 · Grant · Acquired 10,891 · Balance 10,891 F2: The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F2: The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PORTOLA PHARMACEUTICALS INC
Report date July 02, 2020 · Filed July 02, 2020
Section 16 reporting ended · disclosed 2020-07-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 1
1 source rowRow 1 · 2020-07-02 · Disposition to issuer · Disposed 13,194 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes. |
| Restricted Stock UnitsSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 2
1 source rowRow 2 · 2020-07-02 · Disposition to issuer · Disposed 7,281 · Balance 0 F2: At the Effective Time, each restricted stock unit ("RSU") was accelerated and canceled as of immediately prior to, and contingent upon, the Effective Time, in exchange for the right to receive a cash amount equal to the product of (i) the number of shares deliverable under such RSU multiplied by (ii) $18.00. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.94 · Expires 2030-06-11 | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-07-02 · Disposition to issuer · Disposed 11,377 · Balance 0 F3: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-07-02 · Disposition to issuer · Disposed 44,991 · Balance 0 F4: In connection with the Merger, these options were accelerated and canceled without payment. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.
F2: At the Effective Time, each restricted stock unit ("RSU") was accelerated and canceled as of immediately prior to, and contingent upon, the Effective Time, in exchange for the right to receive a cash amount equal to the product of (i) the number of shares deliverable under such RSU multiplied by (ii) $18.00.
F3: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.
F4: In connection with the Merger, these options were accelerated and canceled without payment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2018 Filed Jun 8, 2018 17:56 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-036759 · doc4.xml · nonDerivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 F1 · shares: Grant of Restricted Stock Units ("RSU") in consideration of services rendered. The RSUs fully vest on March 1, 2019, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of such date. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 21:05 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $17.52 | $0.00 |
DisclosureSEC source: 0001415889-18-000910 · form4-06082018_020616.xml · derivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-05 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable at the end of each 3-month period following the date of grant. Read SEC document |
| May 31, 2018 Filed Jun 1, 2018 16:59 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantOption (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $15.80 | Not disclosed |
DisclosureSEC source: 0001209191-18-034754 · doc4.xml · derivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2025-05-30 F2 · price: Not applicable. F1 · derivative.exercise_date: This option vests fully on May 31, 2019, on the one year anniversary of the grant date. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 23:23 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $8.49 | $0.00 |
DisclosureSEC source: 0001415889-18-000013 · form4-01042018_030120.xml · derivative · entry 5 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2018-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable at the end of each 3-month period following the date of grant of June 13, 2008. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 23:23 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $8.06 | $0.00 |
DisclosureSEC source: 0001415889-18-000013 · form4-01042018_030120.xml · derivative · entry 4 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2018-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable at the end of each 3-month period following the date of grant of May 1, 2008. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 23:23 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 25,000 | $30.06 | $751,542.50 |
DisclosureSEC source: 0001415889-18-000013 · form4-01042018_030120.xml · nonDerivative · entry 3 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in October 2017. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.13 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 23:23 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 10,000 | $8.49 | $84,900.00 |
DisclosureSEC source: 0001415889-18-000013 · form4-01042018_030120.xml · nonDerivative · entry 2 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 23:23 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 15,000 | $8.06 | $120,900.00 |
DisclosureSEC source: 0001415889-18-000013 · form4-01042018_030120.xml · nonDerivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 21:28 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $6.84 | $0.00 |
DisclosureSEC source: 0001209191-17-041732 · doc4.xml · derivative · entry 2 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2027-06-20 F1 · derivative.exercise_date: Vests on the earlier of (i) the first anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's next annual meeting of stockholders following the date of grant, subject to continued service as a member of the Board of Directors of the Issuer through such vesting date. Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 21:28 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-041732 · doc4.xml · nonDerivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Read SEC document |
| June 16, 2017 Filed Jun 19, 2017 17:52 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $35.06 | $0.00 |
DisclosureSEC source: 0001209191-17-040908 · doc4.xml · derivative · entry 2 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2027-06-16 F2 · derivative.exercise_date: The Option shall vest as follows: 1/12th of the shares subject to the option shall vest each month after June 1, 2017, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date. Read SEC document |
| June 16, 2017 Filed Jun 19, 2017 17:52 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-040908 · doc4.xml · nonDerivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · shares: Grant of Restricted Stock Units ("RSU") in consideration of services rendered. The RSUs fully vest on March 1, 2018, subject to Reporting Person's Continuous Service as of each such date. Read SEC document |
| June 14, 2017 Filed Jun 17, 2017 00:11 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 2,714 | $0.00 Strike: $44.20 | $0.00 |
DisclosureSEC source: 0001209191-17-040687 · doc4.xml · derivative · entry 2 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,714 Underlying: Common Stock · 2,714 shares Expires 2027-06-14 F2 · derivative.exercise_date: The stock option vests and becomes exercisable on the first anniversary of the grant date, provided that the reporting person remains in continuous service with the issuer through the vesting date. Read SEC document |
| June 14, 2017 Filed Jun 17, 2017 00:11 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 1,357 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-040687 · doc4.xml · nonDerivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,845 F1 · shares: Represents restricted stock units that vest on June 3, 2018, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 13, 2017 Filed Jun 14, 2017 22:15 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $27.25 | $0.00 |
DisclosureSEC source: 0001415889-17-000991 · form4-06142017_030650.xml · derivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-12 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable at the end of each 3-month period following the date of grant. Read SEC document |
| June 02, 2017 Filed Jun 2, 2017 18:04 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantOption (Right to Buy) · Derivative | 7,500 | Not disclosed Strike: $5.90 | Not disclosed |
DisclosureSEC source: 0001209191-17-037411 · doc4.xml · derivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2024-06-01 F2 · price: Not applicable. F1 · derivative.exercise_date: This option vests fully on June 2, 2018, on the one year anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.